Hepatocyte growth factor and Met in drug discovery

Artificial human Met agonists based on macrocycle scaffolds

(2015) Kenichiro Ito et al.   Nature Communications

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

(2013) I. Canadas et al.   CLINICAL CANCER RESEARCH

Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes

(2013) Mizuho Nakayama et al.   CYTOKINE

Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury

(2013) Dong Zhou et al.   KIDNEY INTERNATIONAL

Technologies for the Synthesis of mRNA-Encoding Libraries and Discovery of Bioactive Natural Product-Inspired Non-Traditional Macrocyclic Peptides

(2013) Kenichiro Ito et al.   MOLECULES

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatocyte Growth Factor and Its Receptor Signalling Complex as Targets in Cancer Therapy

(2012) Tracey Martin et al.   Anti-Cancer Agents in Medicinal Chemistry

Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways

(2012) Jens U. Marquardt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype

(2012) F. De Bacco et al.   CANCER RESEARCH

Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands

(2012) Seiji Yano et al.   CANCER SCIENCE

Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases

(2012) Hiroshi Funakoshi et al.   Current Signal Transduction Therapy

Targeting the HGF/Met signaling pathway in cancer therapy

(2012) Fabiola Cecchi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity

(2012) J.-H. Baek et al.   JOURNAL OF IMMUNOLOGY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Hepatocyte growth factor/c-metsignaling is required for stem-cell-mediated liver regeneration in mice

(2011) Tsuyoshi Ishikawa et al.   HEPATOLOGY

Hepatocyte growth factor twenty years on: Much more than a growth factor

(2011) Takahiro Nakamura et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

A new synaptic player leading to autism risk: Met receptor tyrosine kinase

(2011) Matthew C. Judson et al.   Journal of Neurodevelopmental Disorders

Circuit-Specific Intracortical Hyperconnectivity in Mice with Deletion of the Autism-Associated Met Receptor Tyrosine Kinase

(2011) S. Qiu et al.   JOURNAL OF NEUROSCIENCE

Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

(2011) Akio Ido et al.   Journal of Translational Medicine

Human Hepatocyte Growth Factor Promotes Functional Recovery in Primates after Spinal Cord Injury

(2011) Kazuya Kitamura et al.   PLoS One

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Disruption of Hepatocyte Growth Factor/c-Met Signaling Enhances Pancreatic  -Cell Death and Accelerates the Onset of Diabetes

(2010) J. Mellado-Gil et al.   DIABETES

Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia

(2010) H Shigematsu et al.   GENE THERAPY

Evidence of cell-nonautonomous changes in dendrite and dendritic spine morphology in the met-signaling-deficient mouse forebrain

(2010) Matthew C. Judson et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria

(2010) Chunsun Dai et al.   KIDNEY INTERNATIONAL

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

(2010) Louis Vermeulen et al.   NATURE CELL BIOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of c-Met Disrupts Gene Expression Program Required for G2/M Progression during Liver Regeneration in Mice

(2010) Valentina M. Factor et al.   PLoS One

Alternative Proteolytic Processing of Hepatocyte Growth Factor during Wound Repair

(2009) Nils Buchstein et al.   AMERICAN JOURNAL OF PATHOLOGY

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations

(2009) S. Morita et al.   CLINICAL CANCER RESEARCH

c-Met Confers Protection Against Chronic Liver Tissue Damage and Fibrosis Progression After Bile Duct Ligation in Mice

(2009) Arne Giebeler et al.   GASTROENTEROLOGY

Deletion of the Met receptor in the collecting duct decreases renal repair following ureteral obstruction

(2009) Hong Ma et al.   KIDNEY INTERNATIONAL

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin

(2009) A. Tamase et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Deletion of the Met Tyrosine Kinase in Liver Progenitor Oval Cells Increases Sensitivity to Apoptosis in Vitro

(2008) Gaelle del Castillo et al.   AMERICAN JOURNAL OF PATHOLOGY

Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology

(2008) S. Ishibe et al.   DEVELOPMENT

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met

(2008) Cristina Basilico et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY